Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 51, Issue 3, Pages 498-503Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyaa241
Keywords
breast cancer treatment; willingness-to-pay; Japanese; contingent valuation method
Categories
Funding
- MSD Life Science Foundation (Cancer care policy-02)
- National Cancer Center Research and Development Funds [29-A-3, 2020-J-3]
- Japan Agency for Medical Research and Development [JP15ck0106049]
Ask authors/readers for more resources
This study investigates how Japanese breast cancer patients consider the financial value for their life and health, using the contingent valuation method. The results will help establish a cost-effectiveness evaluation axis for standard treatments of breast cancer.
In April 2016, the Japanese government introduced health technology assessment as a response to rising medical expenses due to 'medical innovation'. This study investigates how Japanese breast cancer patients who received treatment in Japan consider the financial value (willingness-to-pay; WTP) for their life and health by using the contingent valuation method (CVM) prospectively. First, 168 patients (84 primary breast cancer patients and 84 metastatic breast cancer patients) were pre-examined their WTP with dichotomous-choice method survey form. Next, 1,596 patients (798 primary breast cancer patients and 798 metastatic breast cancer patients) will be surveyed to their WTP for hypothetical scenarios in CVM. Based on our results, we will construct an evaluation axis from the patients' viewpoint for the cost-effectiveness of clinical trials to establish standard treatments for breast cancer. We believe this research can contribute to create a meaningful healthcare system for patients, clinicians, industries, and healthcare policymakers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available